Key Points: The CFO of Viking Therapeutics sold 57,661 shares of the company for $1.9 million, representing 23.29% of his direct holdings. The sale was done through open-market transactions and included derivative context.

Transaction Summary: The shares were sold for $1.9 million, bringing the total direct ownership to 189,891 shares valued at $6.1 million. The sale was based on a weighted average purchase price of $32.90.

Company Overview: Viking Therapeutics focuses on developing therapies for metabolic and endocrine disorders. The company operates a research-driven business model and targets healthcare providers for potential future commercialization.

Investor Impact: Despite the CFO’s sale, Viking Therapeutics continues to advance its pipeline. The company recently completed a Phase 1 study for an obesity treatment and has ongoing Phase 3 trials. The sale was non-discretionary and aimed to satisfy tax obligations, leaving the CFO with substantial exposure to potential upside.

Read more at Nasdaq: What Investors Should Know About a Viking Therapeutics Insider’s $2 Million Stock Sale